SUN-209 - Gensci155, A Novel Long-Acting IGF-1 Analog for the Treatment of Severe Primary IGF‑1 Deficiency with Lower Hypoglycemic Risk and Superior Efficacy

Senior Author/Primary Investigator(s)

• FR

  Feifei Ren, NA

  Changchun Genescience Pharmaceuticals Co., Ltd., Shanghai, China
  Shanghai, China (People's Republic)

Co-Author(s)

• FR

  Feifei Ren, NA

  Changchun Genescience Pharmaceuticals Co., Ltd., Shanghai, China
  Shanghai, China (People's Republic)
• MC

  Mingjie Chen, NA

  Changchun Genescience Pharmaceuticals Co., Ltd., Shanghai, China
  Shanghai, China (People's Republic)
• HZ

  Hongyang Zhuang, NA

  Changchun Genescience Pharmaceuticals Co., Ltd., Shanghai, China
  Shanghai, China (People's Republic)
• XL

  Xiaolai Lei, Doctor

  Shanghai, China
• FD

  Fangfang Du, NA

  Changchun Genescience Pharmaceuticals Co., Ltd., Shanghai, China
  Shanghai, China (People's Republic)
• PQ

  Peng Qi, scientist

  Changchun Genescience Pharmaceuticals Co., Ltd., Shanghai, China
  Shanghai, China (People's Republic)
• XW

  XIAOZHEN WANG, n/a

  VP
  Changchun Genescience Pharmaceuticals Co., Ltd., Shanghai, China
  Shanghai, China (People's Republic)
• YC

  Yanlin Chen, NA

  Changchun Genescience Pharmaceuticals Co., Ltd., Shanghai, China
  Shanghai, China (People's Republic)

Abstract Poster Presenter(s)

• GS

  Gao Sun, PhD (he/him/his)

  Executive Director
  GenScience Pharma
  SHANGHAI, China (People's Republic)

Co-Author(s)

• GS

  Gao Sun, PhD (he/him/his)

  Executive Director
  GenScience Pharma
  SHANGHAI, China (People's Republic)

Senior Author/Primary Investigator(s)

• LK

  LiShan Kang, scientist

  Changchun Genescience Pharmaceuticals Co., Ltd., Shanghai, China
  Shanghai, China (People's Republic)

Co-Author(s)

• LK

  LiShan Kang, scientist

  Changchun Genescience Pharmaceuticals Co., Ltd., Shanghai, China
  Shanghai, China (People's Republic)